Feb 25, 2026

Subject: Enjoying your free edition of Happiful?

Sender: hello@happiful.com

Last week, you received your free digital issue of Happiful, filled with thoughtful stories, expert insights, and practical support on mental health and wellbeing. If an article or feature resonated with you or made you feel less alone, we’d be grateful if you’d share your experience by leaving a quick Google review. Your feedback helps others find Happiful and supports us in improving the magazine.

Interested in a print copy? Holding Happiful in your hands offers a distraction-free space to slow down, reflect, and take care of yourself. Print subscribers enjoy time away from screens, thoughtful content to savor, and a tangible reminder to pause. Plus, with a 6 or 12-month subscription, UK subscribers receive a FREE ‘Gift of Gratitude’ guided journaling booklet to help build calming habits that reduce stress and boost resilience.

Subscribe now and help spread the love 💕.

Subject: Jeffrey Epstein’s tissue sample ignited a furor in George Church’s lab in 2013

Sender: newsletter@statnews.com

In 2013, a request to sequence Jeffrey Epstein’s tissue sample caused turmoil in geneticist George Church’s lab at Harvard. The request to prioritize Epstein’s sample over others waiting longer shocked lab staff, with some considering quitting. Emails and interviews reveal the details and reactions from the genomics community. Notably, Epstein’s sample’s whereabouts remain unknown.

Also in health news:

• CDC’s No. 2 official Ralph Abraham abruptly resigned after just 2.5 months in office, citing family obligations. His tenure was marked by vaccine skepticism.
• Hepatitis B vaccination rates among newborns peaked in 2023 but have declined recently, correlating with heightened vaccine discourse post-COVID-19.
• Digital twins in healthcare promise personalized health predictions but face challenges translating methods used in aerospace and manufacturing.
• Only 30% of inflammatory bowel disease patients find relief from existing drugs; new treatments are in development with major pharma investments totaling $30 billion.
• Physician advocacy is crucial and must become more vociferous to drive change beyond clinical settings.

Explore more exclusive STAT+ coverage for in-depth biotech, pharma, policy, and life science news.

Subject: 📉 Trump’s reality checks

Sender: vitals@axios.com

As the White House preps for election-year messaging highlighting prescription drug price reductions under President Trump, experts note most Americans may not notice significant savings. Trump’s deals led to commitments from drugmakers for Medicaid discounts and pricing tied to other countries, along with TrumpRx, a direct-to-consumer platform. Yet impacts on typical patient costs are limited.

FDA announced a new pathway to facilitate approval of personalized rare disease treatments, potentially streamlining therapies employing CRISPR gene editing, inspired by the successful “Baby KJ” case.

CDC’s No. 2 official Ralph Abraham resigned abruptly amid controversies over vaccine skepticism and vaccine promotion policy changes.

Additional highlights:

• Medicare’s insolvency projected for 2040, 12 years earlier due to GOP tax and spending policies.
• Novo Nordisk’s weight-loss drug CagriSema underperformed versus Eli Lilly’s Zepbound in late-stage trials, causing stock dips.
• Merck reorganizes pharmaceutical leadership in anticipation of cancer drug patent expiry.
• NY insurer fined for mental health care access errors.

Learn more about Medicare Advantage benefits and recent health policy developments in Axios Vitals.

Subject: COVID’s origins: what we do and don’t know

Sender: briefing@nature.com

Today’s Nature briefing covers:

• Horses produce distinctive two-toned whinnies by combining low-frequency vocal fold sounds with high-pitched larynx whistles, allowing complex communication.
• AI tools are transforming science jobs, reducing demand for writing code and basic data analysis. Concerns exist about the loss of training opportunities for early-career scientists.
• Japan granted conditional approval for pioneering stem-cell therapies for Parkinson’s and heart failure, despite limited clinical testing, raising safety concerns.
• A ninth-century mass grave in Serbia reveals evidence of gender-based violence affecting women and children during the Iron Age.
• China accelerates research on Alzheimer’s disease due to an aging population, exploring innovative drugs, controversial surgeries, and traditional medicine approaches.
• Physicists advocate for nuclear arms control amid treaty expirations, urging unilateral moratoria and the role of researchers in diplomatic communication.
• On COVID-19 origins, major scientific consensus supports a zoonotic origin but calls for continued unbiased investigations as key data remain missing.

Quote of the day: Neuroscientist Dan-E. Nilsson wishes for “one hour back 600 million years ago” to study retina evolution.

Subscribe for free to more Nature Briefing newsletters on climate, AI, cancer, careers, microbiology, and translational research.

Subject: The countdown is on — under a month to Breakthrough East

Sender: marketing@statnews.com

STAT Breakthrough Summit East is less than one month away! Join us in New York City or online on March 19, 2026, for an incisive look into where biotech and life sciences stand after a year of transformative changes.

Featured speakers include:

• Rob Califf, former FDA Commissioner
• Sharon Mates, CEO of Intra-Cellular Therapies
• Chris Klomp, Director of Medicare & Deputy Administrator, CMS
• Jacob Van Naarden, President of Lilly Oncology
• Jessica Malaty Rivera, Infectious Disease Epidemiologist
• Jane Grogan, Biogen Executive VP, and more.

Topics will cover gene editing, confronting health misinformation, Medicare and FDA policy shifts, and much more.

Seats are limited — secure your pass now to connect with thought leaders, innovators, and policymakers shaping the future of health.

Registration is also open for STAT Breakthrough Summit West in May 2026 with early access rates.

Stay Well!